BACKGROUND: Primary intestinal @entity1893 ( @entity1893 ) is a heterogeneous disease with regard to anatomic and histologic distribution. Thus, analyses focusing on primary @entity1893 with large number of @entity1 are warranted. METHODS: We retrospectively analyzed 581 @entity1 from 16 hospitals in Korea for primary @entity1893 in this retrospective analysis. We compared clinical features and treatment outcomes according to the anatomic site of involvement and histologic subtypes. RESULTS: @entity1892 (n = 504, 86.7%) was more frequent than @entity784 (n = 77, 13.3%). @entity1892 ( @entity1892 ) was the most common subtype (n = 386, 66.4%), and extranodal marginal zone @entity1892 ( @entity1074 ) was the second most common subtype (n = 61, 10.5%). @entity1892 mainly presented as @entity66 (Lugano stage I/II) while @entity784 involved multiple intestinal sites. Thus, @entity784 had more unfavourable characteristics such as advanced stage at diagnosis, and the 5-year overall survival (OS) rate was significantly lower than @entity1892 (28% versus 71%, P < 0.001). B symptoms were relatively uncommon (20.7%), and @entity236 was a rare event (7.4%). The ileocecal region was the most commonly involved site (39.8%), followed by the small (27.9%) and large intestines (21.5%). @entity1 underwent surgery showed better OS than @entity1 did not (5-year OS rate 77% versus 57%, P < 0.001). However, this beneficial effect of surgery was only statistically significant in @entity1 with @entity1892 (P < 0.001) not in @entity784 (P = 0.460). The comparison of survival based on the anatomic site of involvement showed that ileocecal regions had a better 5-year overall survival rate (72%) than other sites in consistent with that ileocecal region had higher proportion of @entity1 with @entity1892 who underwent surgery. Age > 60 years, performance status >=  2, elevated serum @entity880 dehydrogenase, Lugano stage IV, presence of B symptoms, and T-cell phenotype were independent prognostic factors for survival. CONCLUSIONS: The survival of @entity1 with ileocecal region involvement was better than that of @entity1 with involvement at other sites, which might be related to histologic distribution, the proportion of @entity5 stage, and need for surgical resection.

Multicenter retrospective analysis of 581 XXXX with primary @entity1893 from the Consortium for Improving Survival of Lymphoma (CISL).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['localized disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1074 :: ('MESH:D018442', 'Disease') :: ['MALT'] @entity784 :: ('MESH:D016399', 'Disease') :: ['T-cell lymphomas', 'T-cell lymphoma'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphomas', 'B-cell lymphoma of mucosa-associated lymphoid tissue', 'DLBCL', 'B-cell lymphoma', 'Diffuse large B-cell lymphoma'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['NHL', 'non-Hodgkin lymphoma', 'intestinal NHL'] @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow invasion']
@entity1 :: (9606,Species) :: ['patients']
